In Silico Prediction of The Antiangiogenesis Activity of Heliannuol Lactone sesquiterpenes Compounds from Sunflower (Heliannthus annuus L.)

Roihatul Muti'ah, Eka Kartini Rahmawati, Tanaya Jati Dhrama Dewi, Alif Firman Firdausy


Heliannuols are sesquiterpenes lactone compounds considered to have anticancer activity on the brain cancer. Cancer cell growth is related to overexpression of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) as a pro-angiogenic pathway, which becomes the main factor of angiogenesis and progression. This research aims to predict anti-angiogenic, toxicity, and physicochemical properties of heliannuols. Physicochemical properties were predicted referred to Lipinski’s rule of five (Lipinski RO5), while absorption, distribution, metabolism, and excretion were predicted by using pkCSM online tool. The toxicity of compounds was predicted by using Protox II online tool, and interaction of the ligand with receptors was predicted by conducting validation (VEGFR-2 (PDB ID: 3WZE)) and molecular docking using Molegro Virtual Docker (MVD). The result revealed that Lipinski RO5 compatible heliannuols had the lowest LD50 2148 mg/kg predictive LD50 predictive values of heliannuol D. The docking result was described by rerank score (RS), representing the bound energy form and compares with Sorafenib as a reference drug. Five medium strength VEGFR-2 chemical substances with rerank score: heliannuol A -56.9496, heliannuol heliannuol B -70.83646, heliannuol C -61,3292, heliannuol D -49.61646, and heliannuol E -75.5164. No better rerank score was recorded for all inhibitors than sorafenib (-128.0683). The heliannuols interacted with amino acid residues Glu885 and Asp1046 that probably conferred the antiangiogenic activity. Taken together, heliannuol D had the greates activity to the target protein and complied Lipinski RO5.

Keywords: anti-angiogenic, toxicity, heliannuol, VEGFR-2, brain cancer, molecular docking.

Full Text:



Agarwal, S., Hartz, A.M. and Elmquist, W.F., 2011, Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up, Curr Pharm Des., 17(26), 2793–802. CrossRef

Babeie, G., Aliarab, A., Abroon, S., Rasmi, and Gholizadeh, A., 2018, Application of Sesquiterpene Lactone: a New Promising Way For Cancer Therapy Based on Anticancer Activity, Journal of Biomedicine and Pharmocotheraphy, 106(2), 239-246. CrossRef

Baell, J., Congreve, M., Leeson, P. and Abad-Zapatero, 2013, Ask the Experts: Past, Present and Future of The RRule of Five, Future Med Chem., 5, 745-752. CrossRef

Bellettato, C.M. and Scarpa, M., 2018, Possible Strategies to Cross The Blood Brain Barrier, Italian Journal of Pediatrics, 44(2), 131. CrossRef

Bell J.S., Koffie, R.M., Rattani, A., Dewan, M.C., Baticulon, R.E., Qureshi, M.M., et al., 2019, Global Incidence of Brain and Spinal Tumors by Geographic Region and Income Level Based on Cancer Registry Data, Journal of Clinical Neuroscience, 66(4), 121-127. CrossRef

Cohen, B.E. and Bangham, A.D., 1972, Diffusion of small non-electrolytes across liposome membranes, Nature, 236(5343), 173-174. CrossRef

Conze, D., Weiss, L., Regen, P.S., Bhushan, A., Weaver, D., Johnson, P. and Rincón, M., 2001, Autocrine Production of Interleukin 6 Causes Multidrug Resistance in Breast Cancer Cells, Cancer Research, 61(24), 8851-8858. Link

Curtin, M.L., Frey, R.R., Heyman, H.R., Soni, N.B., Marcotte, P.A., Pease, L.J., et al., 2012, Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families, Bioorganic & Medicinal Chemistry Letters, 22(9), 3208-3212. CrossRef

Dai, Y., Hartandi, K., Soni, N.B., Pease, L.J., Reuter, D.R., Olson, A.M., et al., 2008, Identification of aminopyrazolo-pyridine ureas as potent VEGFR-PDGFR multitargeted kinase inhibitors, Bioorganic & Medicinal Chemistry Letters, 18(9), 386-390. CrossRef

Firdausy, Mutiah, R. and Eka, 2020, Predicting Pharmacokinetic Profiles of Sunflower’s (Helianthus annuus L.) Active Compounds using in Silico Approach, Journal of Islamic Medicine, 4(1), 1-7. CrossRef

Heffron, T.P., Wei, B., Olivero, A., Staben, S.T., Tsui, V., Do, S., Dotson, J., et al., 2011, Rational Design of Phosphoinositide 3-Kinase Α Inhibitors That Exhibit Selectivity Over the Phosphoinositide 3-Kinase Β Isoform, J. Med. Chem, 54(24), 7815-7833. CrossRef

Jeroen, C.V. and Arie, Z., 2007, Phosphatidylinositol 3-kinase (PI3K) Inhibitors as Anticancer Drugs, Drugs of the Future, 32(6), 537-547. CrossRef

Kesari, S., 2011, Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments, Semin Oncol., 38(Suppl 4), S2–10. CrossRef

Knizetova, P., Ehrmann, J., Hlobilkova, A., Vancova, I., Kalita, O., Kolar, Z., and Bartek, J., 2008, Autocrine regulation of glioblastoma cell-cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay, Journal of Cell Cycle, 7(16), 2553-2561. CrossRef

Kreuger, M.R.O., Grootjans, S., Biavatti, M.W., Vandenabeele, P. and D’Herde, K., 2012, Sesquiterpene lactones as drugs with multiple targets in cancer treatment: focus on parthenolide, Anticancer Drugs, 23(9), 883–896. CrossRef

Kuntala, N., Telu, J., Anireddy, J., and Pal, S., 2017, A Brief Overview on Chemistry and Biology of Benzoxepine, Letters in Drug Design & Discovery, 14(1), 1-13. CrossRef

Lipinski, C.A., Lombardo, F., Dominy, B.W. and Feeney, P.J., 2001, Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings, Advanced Drug Delivery Reviews, 46(18), 3-26. CrossRef

Logarce, D., Domino, D., Maria, A. and Bruno, O. 2017, Computational Analysis of Calculated Physicochemical and ADMET Properties of Pretein-protein Interaction Inhibitor, Scientific Report, 7, 46277. CrossRef

Mannhold, R., Poda, G,I., Ostermann, C. and Tetko, I.V. 2009, Calculation of Molecular Lipophilicity: State of the Art and Comparation of Log P Methods on More Than 96.000 Compounds, Journal of Pharmaceutical Science, 98(3), 861-89. Link

Ministry of Health, 2017, The National Guideline for Medical Service: Brain Tumor, Jakarta: Indonesian Health Office. Link

Nico, B. and Ribatti, D., 2012, Morphofunctional aspects of the blood-brain barrier, Curr Drug Metab., 13(1), 50–60. CrossRef

Paterson, D.A., Conradi, R.A., Hilgers, A.R., Vidmar, T.J. and Burton, P.S., 1994, A nonaqueous partitioning system for predicting the oral absorption potential of peptides, Quant. Struct.-Act. Relat, 13(1), 4-10. CrossRef

Pires, D.E.V., Bllundell, T.L. and Ascher, D.B., 2015, pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures, Journal of Medicinal Chemistry, 58(9), 4066-4072. CrossRef

Pollastri, M.P., 2010, Overview on The Rule of Five, Current Protocols in Pharmacology, 9(12), 1-9. CrossRef

Pratama, 2015, Penambatan Molekuler senyawa aktif Temulawak (Curcuma xantoriza) dengan enzim COX-2 sebagai kandidat Obat Anti Kanker Payudara, Bogor: IPB. Link

Rao, B.S, 2019, Understanding the Globally Harmonized System of Classification and Labeling of Chemical Yhe Purple Book, International Journal of Drug Regulatory Affairs, 7(2), 7-16. CrossRef

Talo, M., Baloglu, U.B., Yıldırım, O., and Acharya, U.R., 2019, Application of Deep Transfer Learning for Automated Brain Abnormality Classification Using Mr Images, Cognitive Systems Research, 54(24), 176–188. CrossRef

Temirak, Mona, and Mahmoud, 2012, Anti-Cancer Agent in Medicine Chemistry, 12(1).


Copyright (c) 2021 Roihatul Mutiah, Eka Kartini Rahmawati, Tanaya Jati Dhrama Dewi, Alif Firman Firdausy

Indexed by:





Indonesian Society for Cancer Chemoprevention